MDAX

EQS-News: ENCAVIS AG acquires six more wind farms in 2023 – Acquisition of further solar parks planned to be accounted for FY 2023

Retrieved on: 
Saturday, January 13, 2024

ENCAVIS had set itself the goal of acquiring a total of 750 GWh of additional electricity production per year in the financial year 2023.

Key Points: 
  • ENCAVIS had set itself the goal of acquiring a total of 750 GWh of additional electricity production per year in the financial year 2023.
  • With the acquisition of the new wind farms alone, this target was almost reached, with a total of 720 GWh per year.
  • In addition, the acquisition of further solar parks, which would still be attributable to the financial year 2023, is planned.
  • “In total, we will increase the newly acquired electricity production in the financial year 2023 to 720 GWh per year.

EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb

Retrieved on: 
Monday, January 8, 2024

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes.
  • Following a successful Phase I study Bristol Myers Squibb announced that a Phase II study for BMS-986419 is scheduled to commence in 2024.
  • In March 2023, Bristol Myers Squibb and Evotec extended and expanded this partnership for an additional 8 years.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “As the first asset from our neuroscience partnership with Bristol Myers Squibb is moving towards a Phase II study, our partnership is still growing in the drug discovery phase as well.

EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

Retrieved on: 
Thursday, January 4, 2024

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).
  • The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and develop new therapeutics.
  • Evotec will receive R&D funding from Owkin and is eligible to earn performance milestone payments and royalties on product sales.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “Owkin and Evotec both feel there is something special brewing by convergence between A.I.

EQS-News: Evotec announces CEO transition

Retrieved on: 
Wednesday, January 3, 2024

Werner Lanthaler will support a smooth and prompt transition of ongoing projects in the coming weeks.

Key Points: 
  • Werner Lanthaler will support a smooth and prompt transition of ongoing projects in the coming weeks.
  • In the meantime, Dr Mario Polywka, currently Supervisory Board member and former COO of Evotec, agreed to serve as interim CEO.
  • The company sees itself on a strong path, especially based on its paradigm-shifting technologies, such as PanOmics, iPSC and Just – Evotec Biologics.
  • With PanOmics driven drug-discovery, iPSCs, and Just – Evotec Biologics the company is set up for long-term global leadership and success.

EQS-News: Krones shares return to MDAX index

Retrieved on: 
Saturday, December 30, 2023

As a result of the review, Krones AG shares are to be promoted from the SDAX to the MDAX index with effect from 18 December 2023, thus returning to the 50-share mid-cap index after only three months.

Key Points: 
  • As a result of the review, Krones AG shares are to be promoted from the SDAX to the MDAX index with effect from 18 December 2023, thus returning to the 50-share mid-cap index after only three months.
  • “We are pleased that Krones shares are now rejoining the MDAX and that we have thus achieved our goal of a rapid return to the mid-cap index”, said Krones CEO Christoph Klenk.
  • Krones shares initially left the DAX index family altogether on 18 September 2023 because the company temporarily ceased to comply with a basic criterion for index membership.
  • Krones took immediate action in response and prepared the way back to the DAX index family.

EQS-News: Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes

Retrieved on: 
Saturday, December 30, 2023

Potential teratogenicity of drug candidates, i.e., their ability to cause defects in a developing foetus, is usually assessed very late in the drug discovery process using time- and cost-intensive in vivo models.

Key Points: 
  • Potential teratogenicity of drug candidates, i.e., their ability to cause defects in a developing foetus, is usually assessed very late in the drug discovery process using time- and cost-intensive in vivo models.
  • Using human induced pluripotent stem cell (“iPSC”) technology, Evotec has developed an in vitro teratogenicity platform with high-throughput capability, which enables cost effective de-risking of drug candidates early in the drug discovery process.
  • The grant provides GHDC members receiving funding from the foundation access to Evotec’s high-throughput teratogenicity platform at no extra cost.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very proud to receive this grant from the Bill & Melinda Gates Foundation and thereby join the Global Health Discovery Collaboratory as a Collaboratory Platform.

EQS-News: Encavis Asset Management supports the sale of a Renewable Energy portfolio with a total capacity of 93 megawatts for an institutional investor

Retrieved on: 
Saturday, December 30, 2023

Neubiberg/Munich, 29 November 2023 – Encavis Asset Management, a subsidiary of MDAX-listed wind and solar park operator Encavis AG, has completed the sale of a Renewable Energy portfolio with a total capacity of 93 megawatts (MW) for an institutional investor.

Key Points: 
  • Neubiberg/Munich, 29 November 2023 – Encavis Asset Management, a subsidiary of MDAX-listed wind and solar park operator Encavis AG, has completed the sale of a Renewable Energy portfolio with a total capacity of 93 megawatts (MW) for an institutional investor.
  • The European portfolio, to date successfully managed by Encavis Asset Management (Encavis AM), comprises a total of nine wind farms with a total capacity of 76 MW and two solar parks with a total capacity of 17 MW.
  • Encavis Asset Management AG offers institutional investors tailor-made portfolios and fund solutions for investments in the growth market of Renewable Energies.
  • This corresponds to a total saving of around 0.8 million tonnes of CO2 per year stand-alone for the Encavis AG.

EQS-News: Gerresheimer AG: Guido Pickert to head up Investor Relations at Gerresheimer

Retrieved on: 
Saturday, December 30, 2023

Guido Pickert will join Gerresheimer AG, an innovative system and solution provider and a global partner for the pharma, biotech, and cosmetic industries, as Vice President Investor Relations with effect from January 2024.

Key Points: 
  • Guido Pickert will join Gerresheimer AG, an innovative system and solution provider and a global partner for the pharma, biotech, and cosmetic industries, as Vice President Investor Relations with effect from January 2024.
  • Pickert comes from Aixtron SE, where he most recently served as Vice President Investor Relations & Corporate Communications.
  • Guido Pickert studied business administration and international product management before launching his career at the IR agency Value Relations in 1999.
  • Starting in January 2024, he will take on overall responsibility for Investor Relations at Gerresheimer AG.

EQS-News: GRENKE Corporate Governance scores top position in SDAX

Retrieved on: 
Saturday, December 30, 2023

Compared to the previous year, GRENKE improved significantly by 3.94 percentage points (2022: 3rd place SDAX, 74.13 %).

Key Points: 
  • Compared to the previous year, GRENKE improved significantly by 3.94 percentage points (2022: 3rd place SDAX, 74.13 %).
  • The DVFA Scorecard annually evaluates the quality of corporate governance of companies listed in the German DAX, MDAX and SDAX.
  • “We are proud, to have achieved a top position in the SDAX for our corporate governance again”, states Dr. Sebastian Hirsch, CEO of GRENKE AG.
  • “A strong corporate governance is the foundation for trust in the capital market and is of high importance to us.

EQS-News: Deutsche Börse admits Mutares to the SDAX

Retrieved on: 
Saturday, December 30, 2023

Effectiveness of inclusion in the selection index as of December 18, 2023

Key Points: 
  • Effectiveness of inclusion in the selection index as of December 18, 2023
    Munich, December 6, 2023 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) will be promoted to the SDAX.
  • This was decided by Deutsche Börse in its regular review of the small-cap index yesterday.
  • This makes Mutares one of the 70 most liquid and largest listed companies in Germany below the DAX and MDAX in terms of free-float market capitalization.
  • The promotion to the SDAX marks another milestone in the Company's success story since its IPO in 2008.